2016. Cost-effectiveness profile, organizational implications and patient preferences on the use of exogenous TSH therapy (Thyrogen®) vs. THW in thyroid residue ablation in Italy. Farmeconomia. Health economics and therapeutic pathways. 17, 3 (Oct. 2016). DOI:https://doi.org/10.7175/fe.v17i3.1264.